Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 10;16:5343–5356. doi: 10.2147/IJN.S317046

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Otake et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

In vitro transcorneal penetration of nFBL-FC in rabbit corneas at 37 °C.

Notes: (A), (C), (E) Penetration profiles for the FL (A), BF (C) and LV (E) in nFBL-FC and the corresponding CA-eye drops. (B), (D), (F) AUC_penetration of FL (B), BF (D) and LV (F) in nFBL-FC and the corresponding CA-eye drops. The data are expressed as mean±S.E.n=5–8. *P<0.05 vs CA-eye drops for each category. The corneal penetrations of the FL, BF and LV in nFBL-FC were higher than those in the corresponding CA-eye drops.

Abbreviations: AUC, area under the drug concentration–time curve; BF, bromfenac; CA, commercially available; FL, fluorometholone; LV, levofloxacin; mFBL-FC, fixed-combination eye drops based on fluorometholone microparticles and bromfenac/levofloxacin solution; nFBL-FC, fixed-combination eye drops based on fluorometholone nanoparticles and bromfenac/levofloxacin solution.